Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2023-08-21 Regulatory Filings
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal disclosure from Hana Pharm regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, counterparty (Mundipharma Medical Company), contract period, and terms. Since this is a specific regulatory disclosure of a material business contract that does not fit into financial reporting, M&A, or other specific categories, it falls under the general regulatory filing category.
2023-08-21 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Hana Pharm Co., Ltd., covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial data, business operations, and management information, which is characteristic of an interim/quarterly report. It is not an announcement of a report, but the report itself. H1 2023
2023-08-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their personal share transactions. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2023-07-28 Korean
[기재정정]사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an Annual Report (사업보고서) filed by Hana Pharm Co., Ltd. It explicitly references the original filing date of March 22, 2023, and provides corrected sections regarding audit opinions, internal control, and management discussions. Since this is a formal amendment to an existing Annual Report (10-K equivalent in the Korean market), it is classified under the 10-K category as it constitutes part of the annual reporting cycle. FY 2022
2023-07-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company directors or major shareholders. Based on the provided categories, this fits the 'Director's Dealing' (DIRS) classification, which covers personal share transactions by company directors and executives.
2023-06-02 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hana Pharm Co., Ltd. for the period ending March 31, 2023. It contains detailed financial data, business operations, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full content of the quarterly filing. Q1 2023
2023-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.